

# World Conference on Pharmacometrics 2016

## Poster program

Monday, 22 August 2016 12.15 pm - 1.15 pm

Poster	Title	Presenter	Theme
200	Multi-scale system pharmacology modelling pipeline to assess the prophylactic efficacy of NRTIs against HIV-1	Sulav Duwal	1. The optimal design, analysis and translation of infectious disease human challenge models
201	Joint modelling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers	France Mentre	1. The optimal design, analysis and translation of infectious disease human challenge models
202	Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses	France Mentre	9. Other
203	Population pharmacokinetics of artesunate and dihydroartemisinin in patients with sensitive and resistant malaria infection	Thanaporn Wattanakul	1. The optimal design, analysis and translation of infectious disease human challenge models
204	Model-based assessment of benefits and risks of rt-PA treatment in acute ischemic stroke	Jinju Guk	2. Hospital-based pharmacometrics
205	An optimal sampling schedule for children receiving cephazolin +/- vancomycin for cardiopulmonary bypass	Jacqueline Hannam	2. Hospital-based pharmacometrics
206	Repeated time-to-event analysis of <i>Pseudomonas aeruginosa</i> and <i>Aspergillus fumigatus</i> acquisitions in children with cystic fibrosis	Sabariah Noor Harun	2. Hospital-based pharmacometrics
207	A pilot study to investigate the relationship between doxorubicin and doxorubicinol pharmacokinetics and cardiotoxicity in children and adolescents with cancer	Stefanie Hennig	2. Hospital-based pharmacometrics
208	Development of a biomarker-based prediction model of disease progression during chemotherapy in young adolescents	Young A Heo	2. Hospital-based pharmacometrics
209	Survival and toxicity in obese lymphoma patients receiving chemotherapy dosed on capped body surface area	Julia Korell	2. Hospital-based pharmacometrics
210	Population pharmacokinetic analysis of Levetiracetam in adult Malaysian patients with epilepsy	Yoke-lin Lo	2. Hospital-based pharmacometrics
211	A viral kinetic model for severe human cytomegalovirus infections in immunocompromised paediatric patients	Ben Margetts	2. Hospital-based pharmacometrics
212	Development of an interactive application to assist clinicians in the dose adjustment of voriconazole	David McDougall	2. Hospital-based pharmacometrics
213	A PBPK model of phenytoin after intravenous administration of fosphenytoin sodium in Japanese pediatric patients	Masayoshi Nakakuni	2. Hospital-based pharmacometrics
214	Clinical pharmacometrics for personalized dosing of teicoplanin	Kazutaka Oda	2. Hospital-based pharmacometrics
215	Bayesian forecasting versus clinical practice for intravenous busulfan dose adjustment in paediatric stem cell transplantations	Lachlan Paterson	2. Hospital-based pharmacometrics
216	Population pharmacokinetic modeling of Atazanavir/r in Thai HIV-infected patients: an aid for optimal dose finding	Baralee Punyawudho	2. Hospital-based pharmacometrics
217	Modelling and simulation of fluconazole in critically ill adult patients	Indy Sandaradura	2. Hospital-based pharmacometrics
218	Mechanistic model for calcium treatment effect in calcium-parathyroid hormone homeostasis after thyroidectomy in Koreans	Mijeong Son	2. Hospital-based pharmacometrics
219	Operational characteristics of saemix, an R package implementing the SAEM algorithm	Emmanuelle Comets	3. Language, libraries and connectors
220	<i>nlmixr</i> : an open-source package for pharmacometric modelling in R	Rik Schoemaker	3. Language, libraries and connectors
221	Integrated population PK-PD model of pimobendan effects on the cardiovascular system in the dog	David Foster	9. Other
222	Internal deterministic identifiability	Vijay Kumar Siripuram	9. Other
223	Toxicokinetics of Endotoxin and its induction of pro-inflammatory cytokines tumor necrosis factor $\alpha$ and interleukin-6	Anders Thorsted	9. Other
224	A QSP model to predict the effects of different anticoagulants on the human coagulation network	Mirjam Trame	9. Other
225	Population modelling of functional disability in early rheumatoid arthritis treated according to a treat-to-target strategy	Jessica Wojciechowski	9. Other
226	Population of pharmacokinetics of tanezumab in patients with chronic low back pain	Ruja Xie	9. Other

# World Conference on Pharmacometrics 2016

## Poster program

Tuesday, 23 August 2016 12.15 pm - 1.15 pm

Poster	Title	Presenter	Theme
227	Understanding identifiability of random effects in mixed effects models	Leon Aarons	4. Bridging the gap between pharmacometricians and statisticians
228	How pharmacometrics can improve the power of pharmacogenetic studies	Julie Bertrand	4. Bridging the gap between pharmacometricians and statisticians
229	Imputation methods to correct for overestimated shape parameter of Weibull hazard function in time-to-event modeling	Dong-seok Yim	4. Bridging the gap between pharmacometricians and statisticians
230	Application of Bayesian inference to a model of the dynamics of Plasmodium falciparum parasitaemia in severe malaria patients	Sophie Zaloumis	4. Bridging the gap between pharmacometricians and statisticians
231	Physiologically based pharmacokinetic models for Trastuzumab using serial concentrations measured by optical imaging in mouse	Hyeongseok Lim	6. Application of models for solid tumor dynamics to oncology drug development
232	Population plasma and urine pharmacokinetics of Ivabradine and its active metabolite in Korean healthy volunteers	Hyeongseok Lim	5. Pharmacometric approaches to optimize dose selection
233	Pharmacokinetic and Pharmacodynamic analysis of GCC-4401C, a novel direct factor Xa inhibitor, in healthy volunteers	Hyeongseok Lim	5. Pharmacometric approaches to optimize dose selection
234	Pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of lobeglitazone	Hyang-Ki Choi	5. Pharmacometric approaches to optimize dose selection
235	Evaluating methods using pharmacokinetic information to design dose-finding phase I studies in small populations	Emmanuelle Comets	5. Pharmacometric approaches to optimize dose selection
236	Tofacitinib Pharmacokinetics in moderate-to-severe Crohn's Disease patients in phase 2 induction and maintenance studies	Chenhui Deng	5. Pharmacometric approaches to optimize dose selection
237	The pharmacokinetics of AT9283, a selective inhibitor of aurora kinases, in adults and children with solid tumours and leukemia	Janna Duong	5. Pharmacometric approaches to optimize dose selection
238	Development of an interactive tool to explore paediatric doses and sample size for paediatric trials	Bruce Green	5. Pharmacometric approaches to optimize dose selection
239	Exposure-response modeling of longitudinal Likert pain scores following treatment with Neulastin	Yaming Hang	5. Pharmacometric approaches to optimize dose selection
240	Dose selection for rifabutin in combination with HIV-protease inhibitors	Stefanie Hennig	5. Pharmacometric approaches to optimize dose selection
241	Evaluation of intraocular penetration of levofloxacin after administration drop solution by high performance liquid chromatography and comparison with ciprofloxacin	Amir Heydari	5. Pharmacometric approaches to optimize dose selection
242	Population Pharmacokinetic profile of zabofloxacin in Korean subjects	Min-Gul Kim	5. Pharmacometric approaches to optimize dose selection
243	Simulation analysis to explore the optimal combination of pregabalin and duloxetine	Ah Ra Koh	5. Pharmacometric approaches to optimize dose selection
244	Mechanism-based model to quantitatively characterise the impact of altered piperacillin pharmacokinetics on bacterial killing and resistance	Cornelia Landersdorfer	5. Pharmacometric approaches to optimize dose selection
245	Utilisation of a pharmacokinetic model based approach to optimise paediatric dose selection and study design	Fran Stringer	5. Pharmacometric approaches to optimize dose selection
246	Optimal Ranirestat dose estimation in patients with diabetic sensorimotor polyneuropathy: non-linear population pharmacokinetic pharmacodynamic approach	Takeshi Takagaki	5. Pharmacometric approaches to optimize dose selection
247	Mechanism-based PK/PD modelling approach to optimise synergistic combinations against carbapenem- and aminoglycoside (AGS)-resistant clinical isolates of Pseudomonas aeruginosa (Pa)	Rajbharan Yadav	5. Pharmacometric approaches to optimize dose selection
248	Exploring the effect of high-flux haemodialysis on oral amoxicillin/clavulanic acid using a semi-mechanistic model	Katrina Hui	9. Other
249	Translation between two models; application with integrated glucose homeostasis models	Moustafa Ibrahim	9. Other
250	Evaluation of covariate effect size based on parameter variability	Takayuki Katsube	9. Other
251	A simulation study to evaluate treatment effect of tamoxifen by CYP2D6 genotypes compared with AIs	Kwan Cheol Pak	9. Other
252	Mechanism-based modelling to assess suppression of bacterial resistance by high intensity, short duration tobramycin exposure	Vanessa Rees	9. Other
253	Warfarin maintenance dose prediction models do not work for patients who would benefit the most	Shamin Saffian	9. Other

Poster session sponsored by



# World Conference on Pharmacometrics 2016

## Poster program

Wednesday, 24 August 2016 12.15 pm - 1.15 pm

Poster	Title	Presenter	Theme
254	Influence of body composition on disposition of highly fat distributed compound analyzed by PBPK modeling	Akihiko Goto	7. Influence of body composition and age on pharmacokinetics
255	Effect of developmental growth and FcRn expression on the pharmacokinetics of monoclonal antibodies in mice	Bernd Meibohm	7. Influence of body composition and age on pharmacokinetics
256	Amikacin pharmacokinetics in pediatric patients with burn injuries compared to those with oncology conditions	Catherine Sherwin	7. Influence of body composition and age on pharmacokinetics
257	Predicting the pharmacokinetic changes in fluoxetine during pregnancy	Manoranjenni Chetty	7. Influence of body composition and age on pharmacokinetics
258	A PBPK/PD model to describe the impact of CYP2C19 polymorphisms on the response to clopidogrel	Manoranjenni Chetty	8. Pharmacometric applications in non-communicable diseases
259	Nonlinear pharmacokinetic modeling of rheumatoid arthritis biologics after intravenous and subcutaneous administration in rats	In-hwan Baek	8. Pharmacometric applications in non-communicable diseases
260	Model-based meta-analysis on the efficacy of pharmacological treatments for idiopathic pulmonary fibrosis	Phyllis Chan	8. Pharmacometric applications in non-communicable diseases
261	Population pharmacokinetics of Reditux <sup>TM</sup> , a biosimilar Rituximab, in Diffuse Large B Cell Lymphoma	Vikram Gota	8. Pharmacometric applications in non-communicable diseases
262	Pharmacokinetic study of Boswellic acids formulated as solid lipid Boswellia serrata particules in healthy volunteers	Preeti Kulkarni	8. Pharmacometric applications in non-communicable diseases
263	Population pharmacokinetic analysis of Daclatasvir, Asunaprevir and Beclabuvir in HCV-infected non-Japanese and Japanese subjects	Mayu Osawa	8. Pharmacometric applications in non-communicable diseases
264	Application of QSP model to evaluate xCT inhibition as target for central nervous system diseases	Mike Reed	8. Pharmacometric applications in non-communicable diseases
265	The application of continuous-time Markov exposure-response model to sIGA – the case study of nemolizumab	Tomohisa Saito	8. Pharmacometric applications in non-communicable diseases
266	Population pharmacokinetic-pharmacodynamic model of prednisolone in lupus nephritis patients	Nurul Azrin Abd Rahman	9. Other
267	Quantitative review and meta-models of gastrointestinal pH to help inform mechanistic oral absorption models	Ahmad Abuhelwa	9. Other
268	Faster ADVAN-style analytical solutions for simulations from common pharmacokinetic models	Ahmad Abuhelwa	9. Other
269	Quantitative review and meta-models of gastrointestinal transit times to help inform mechanistic oral absorption models	Ahmad Abuhelwa	9. Other
270	Population pharmacokinetics of OZ439 in patients with falciparum and vivax malaria	Piyanan (Jill) Assawasuwannakit	9. Other
271	A population dose-response analysis of Lurasidone in treatment of major depressive disorder with mixed features	Yu-Yuan Chiu	9. Other
272	Population pharmacokinetic analysis of 2'-benzoyloxycinnamaldehyde and its metabolites	Sangmin Choe	9. Other
273	Quantitative model diagrams (QMD): a new perspective in model evaluation	Benjamin Guiastrenec	9. Other
274	Placebo effect in overactive bladder clinical studies: longitudinal model-based meta-analysis of micturitions	Chihiro Hasegawa	9. Other
275	Population pharmacokinetic model of doxycycline plasma concentrations – pooled study data	Ashley Hopkins	9. Other
276	Comparison between non-compartmental analysis and non-linear mixed effects in determining bioequivalence for two-compartment drugs	Jim Hughes	9. Other
277	Pharmacokinetic modeling and simulation analysis of LCB01-0371, a novel oxazolidinone antibiotic	Hyeongseok Lim	9. Other
278	Pharmacokinetic and pharmacodynamic modeling and simulation analysis of a novel donepezil patch formulation	Hyeongseok Lim	9. Other
279	Examining the predictive performance of equations to estimate glomerular filtration rate in paediatric oncology patients	Carolina Llanos	9. Other
280	Population pharmacokinetic model of gentamicin in paediatric oncology patients	Carolina Llanos	9. Other